Difference between revisions of "Team:Sheffield/episode5"
| Line 340: | Line 340: | ||
<h2>What we failed to do and what we should have done</h2> | <h2>What we failed to do and what we should have done</h2> | ||
| − | <p> Our work in human practices is limited to the extent that for each stakeholder | + | <p> Our work in human practices is limited to the extent that for each stakeholder we have only spoken with one individual. This size of sample is far from representative. If future iGEM teams would like to build on our work, for example, more than one doctor and patient should be contacted. </p> |
| − | <p> In terms of studying how our device would impact the world, we did not speak to the the NHS(National health service) or any private health | + | <p> In terms of studying how our device would impact the world, we did not speak to the the NHS(National health service) or any private health providers such as Bupa. This means we are unable to forecast introduction of our device into the market. </p> |
| − | <p> Finally, due to time constraint, we also failed to have a ready device for our experts or users such as patients to test it, making us lack of device re-specifications | + | <p> Furthermore, we did not model the cost of device and how much unnecessary antibiotics would be reduced if our device were to exist. This is due to a lack of available data and inability of the economist on our team. </p> |
| + | |||
| + | <p> Finally, due to time constraint, we also failed to have a ready device for our experts or users such as patients to test it, making us lack of device re-specifications. </p> | ||
Revision as of 16:58, 17 October 2016
|
SHORTCOMINGS |
|
|---|
|
|
|
||
|---|---|---|---|---|
|
|
What we failed to do and what we should have done
Our work in human practices is limited to the extent that for each stakeholder we have only spoken with one individual. This size of sample is far from representative. If future iGEM teams would like to build on our work, for example, more than one doctor and patient should be contacted.
In terms of studying how our device would impact the world, we did not speak to the the NHS(National health service) or any private health providers such as Bupa. This means we are unable to forecast introduction of our device into the market.
Furthermore, we did not model the cost of device and how much unnecessary antibiotics would be reduced if our device were to exist. This is due to a lack of available data and inability of the economist on our team.
Finally, due to time constraint, we also failed to have a ready device for our experts or users such as patients to test it, making us lack of device re-specifications.
